Hims & Hers: Wegovy Deal Fuels Growth

Hims & Hers, Inc. (HIMS) stock has risen 41% since my last update, driven by product and international expansion. Q1 revenue reached $608 million, up 4% YoY, with U.S. operations declining but international revenue surging 969% to $78 million. The U.S. segment faced tough comps due to prior GLP-1 sales and shipping cadence, while international growth was fueled by ZAVA and Livewell acquisitions.

Seeking Alpha • 10 hours ago

Hims & Hers Stock Stabilizes After Upsized $350 Million Convertible Note Offering

Hims & Hers Health Inc (NYSE:HIMS) shares are trading flat during Tuesday's pre-market session as traders continue to digest the company's convertible notes offering.

Benzinga • May 19, 2026

Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss.

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circling the wreckage.

24/7 Wall Street • May 18, 2026

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant.

Business Wire • May 18, 2026

Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of.

Business Wire • May 19, 2026

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.

24/7 Wall Street • May 18, 2026

Hims & Hers Health: GLP-1 Drama Ending Signals Return To Growth

Hims & Hers Health has returned to growth mode after volatility from the GLP-1 transition, yet trades near multi-year lows. The online health platform guided up 2026 revenues to $3B, exceeding consensus, and does not yet reflect the Eucalyptus acquisition. The company faces short-term margin pressure from branded GLP-1 drugs and international scaling, but the long-term target remains at least 20% EBITDA margins in 2030.

Seeking Alpha • May 17, 2026

HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell?

Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss care.

Zacks Investment Research • May 15, 2026

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • May 15, 2026

Hims & Hers Health: The Stock Is On Sale, Buy It

Hims & Hers Health delivered a misunderstood Q1-26, raising FY-26 guidance and reaffirming 2030 revenue and EBITDA targets despite negative sentiment. The transition from compounded to branded GLP-1s pressured margins, but normalized gross margins remain robust and marketing spend is a lever for profitability. Subscriber growth is poised to reaccelerate, with expectations of 100k new weight loss subscribers per month via the Novo partnership, supporting a 30–35% YoY increase.

Seeking Alpha • May 15, 2026